XML 106 R54.htm IDEA: XBRL DOCUMENT v3.20.1
RESTATEMENT (Tables)
 12 Months Ended
Dec. 31, 2019
RESTATEMENT  
Summary of impact on consolidated financial statements

The impact to the 2018 and 2017 consolidated financial statements is as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2018

 

2018

 

2017

 

2017

Consolidated Statements of Financial Position

    

As restated

    

As previously reported

    

As restated

    

As previously reported 

 

 

 

 

 

 

 

 

 

 

 

 

 

Inventory

 

$

318,135

 

$

258,742

 

$

398,556

 

$

398,556

Research and development supplies

 

 

1,274,653

 

 

 —

 

 

1,274,653

 

 

 —

 

 

 

 

 

 

 

 

 

 

 

 

 

Deficit

 

 

(331,401,149)

 

 

(332,735,195)

 

 

(223,417,674)

 

 

(224,692,327)

 

 

 

 

 

 

 

 

 

 

 

 

 

Consolidated Statements of Loss and Comprehensive Loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product development and clinical trials

 

$

16,001,464

 

$

16,060,857

 

$

16,214,439

 

$

17,489,092

Operating loss

 

 

(32,410,690)

 

 

(32,470,083)

 

 

(30,874,255)

 

 

(32,148,908)

Loss for the year

 

 

(107,983,475)

 

 

(108,042,868)

 

 

(21,634,068)

 

 

(22,908,721)

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss per share

 

$

(76.26)

 

$

(76.30)

 

$

(265.37)

 

$

(281.94)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Consolidated Statements of Cash Flows

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss for the year

 

$

(107,983,475)

 

$

(108,042,868)

 

$

(21,634,068)

 

$

(22,908,721)

Net change in non-cash working capital items

 

 

(59,393)

 

 

 —

 

 

(1,274,653)

 

 

 —